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Several specific inhibitors for plasminogen activators have been isolated from various organs and cell lines, those from 
human placenta and the human monocyte-like cell line U-937 being virtually identical. The reaction between this type 
of inhibitor, designated as type-2, and high-M, and low-M, urokinase-type plasminogen activators was followed by re- 
versed-phase high-performance liquid chromatography and gel electrophoresis. The components, their stable complexes 
and their dissociation and cleavage products could be clearly identified in both systems. The amino acid sequence of 
the inhibitor at the cleavage site was determined to be -Met-Thr-Gly-ArgJThr-Gly-His-Gly-. A 35-residue carboxy-termi- 
nal fragment was found to be released. 
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1. INTRODUCTION 
Plasminogen activators belong to the family of 
serine proteinases and are responsible for the con- 
version of the proenzyme plasminogen to its active 
form, plasmin. Two physiologically important ac- 
tivators are known: urokinase-type (u-PA) and 
tissue-type activator (cf. [l]). Specific inhibitors 
(PAI), which lack a direct effect on plasmin, 
regulate the activity of the activators. Recently, 
such inhibitors have been isolated from several 
organ types and cell line cultures (cf. [2]). The in- 
hibitors purified from human placenta [3,4] and 
from the human monocyte-like histiocytic lym- 
phoma cell line U-937 [5,6] are immunologically 
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related and occur in virtually identical forms. They 
are denoted as placenta-type PAIs or type-2 PAIs 
(PAI-2) and differ in immunological, protein 
chemical [7] and inhibitory properties from type-l 
PAIs (PAI-I), i.e. endothelial cell-type PAIs. 
During the reaction between urokinase-type (u- 
PA) or tissue-type plasminogen activators with 
PAIs, an enzyme-inhibitor complex is formed and 
then the inhibitor is cleaved; the complex can be 
dissociated under alkaline conditions. The various 
stages of the reaction have been observed by means 
of SDS-PAGE for both type-l PA1 [8] and type-2 
PA1 [4,6]. For PAI- the sequence around the 
cleavage site was determined by protein chemical 
methods 191. Here, a novel, reversed-phase HPLC- 
based procedure has been employed to monitor the 
appearance and disappearance of the components 
in the reaction between PAI- and high- and low- 
M, U-PAS. PAI- interacts in analogous ways with 
high- and low-M, U-PAS, even though the latter 
lacks a large N-terminal part of the structure as 
compared to the high-M, form [l]. The cleavage 
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site in PAI- was determined by protein sequence 
analysis. 
2. EXPERIMENTAL 
2.1. Materials 
PAI- was isolated from human placenta and the human 
histiocytic lymphoma cell line U-937 as described [4,6]. Pure 
high- and low-M, U-PAS (100000 and 180000 IWmg, respec- 
tively) were a gift from Serono (Freiburg, FRG). 
2.2. Reaction between u-PA and PAI- 
For complex formation solutions of 0.05 mg PAI- prepara- 
tions in 0.15 ml of 0.05 M sodium phosphate, pH 7.2, were 
mixed with equimolar amounts of high- or low-M, u-PA in 
0.05 ml of 0.1 M NaCl and allowed to incubate for 15 min at 
room temperature. For complex dissociation 0.2 ml of 1 M am- 
monia was added and the samples left for 15 or 60 min at 37°C. 
All reactions were stopped by addition of 0.5 vol. of 70% for- 
mic acid before HPLC analysis and SDS sample buffer before 
SDS-PAGE analysis, respectively. 
2.3. Cyanogen bromide cleavage 
About 0.15 mg PAI- was dissolved in 0.1 ml of a solution 
containing 10% (w/v) CNBr in 70% formic acid. After 2 h at 
room temperature xcess reagents were removed by a stream of 
N2 [IO]. 
2.4. High-performance liquid chromatography 
Separations were performed on an LKB HPLC system using 
a Nucleosil 300-10 Cis reversed-phase column (25 X 0.46 cm, 
Macherey-Nagel, Diiren, FRG). For elution linear gradients 
between 5 and 70% (v/v) acetonitrile in 0.1% (v/v) 
trifluoroacetic acid were employed at l%/min and a flow rate 
of 1 ml/min at room temperature [l 11. 
2.5. Polyacrylamide gel electrophoresis 
Electrophoretic analysis [12] was carried out in 0.1 x 10 x 
10 cm vertical slab gels containing 0.1% SDS, 10% 
polyacrylamide and no mercaptoethanol (apparatus from 
Biometra). 
2.6. Amino acid sequence analysis 
Sequence determination was performed by the Edman 
degradation method in a prototype spinning-cup sequenator 
1131. 
3. RESULTS AND DISCUSSION 
The reaction between high-M, u-PA and PA13 
was analysed using an established method [4,6], 
SDS-PAGE (fig.l), and a novel procedure, 
reversed-phase HPLC (figs 2,3), in parallel. The 
results obtained with both methods were in good 
agreement. The SDS-PAGE system gave addi- 
tional information about the molecular size of the 
components, but those components with the lowest 
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Fig.1. Reaction between PAI- and u-PA monitored by non- 
reducing 10% SDS-PAGE; staining with Coomassie blue. 
Starting material: PAI-2 (lane 4), high-Mr u-PA (lane l), low- 
M, u-PA (lane 5). Complexes with: high-k& u-PA (lane 2), low- 
M, u-PA (lane 6). Partly dissociated complexes with: high-M, u- 
PA (lane 3), low-M, u-PA (lane 7). M, values (x lo-‘) are 
indicated on the right. 
A& values could not be detected. The advantages of 
the HPLC system lie in the facts that the com- 
ponents separated directly could be submitted to 
protein chemical identification, and furthermore, 
that all components, even those of low-M, could be 
observed and quantitated. 
For the activator-inhibitor reaction equimolar 
amounts of u-PA and PAI- were mixed. Com- 
plexes sufficiently stable to allow SDS-PAGE or 
HPLC analysis were formed. The A& of the com- 
plex with high-M, u-PA appeared to be 82000 and 
that with low-M, u-PA 62000 (fig.l), which is 
somewhat lower than expected from the sum of the 
components’ kf, values, i.e. about kf, 54000 and 
33000 for the U-PAS and M, 45000 for PAI-2. On 
HPLC analysis components with retention times 
intermediate between those of the U-PAS and 
PAI- appeared (figs 2,3). Complete complex for- 
mation had occurred as judged by the absence of 
free activators or inhibitor. HPLC analysis clearly 
demonstrated that at this stage a low-M, compo- 
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Fig.2. Reaction between PAI- and high-M, u-PA monitored by reversed-phase HPLC. (a) Starting materials (separate, superimposed 
HPLC analysis), (b) complex formation, (c) partial and (d) complete dissociation. 
nent had already been released (figs 2,3, panels b, 
peak labelled C-term). 
The u-PA-PAI- complexes were dissociated by 
incubation with ammonia. After 15 min partial 
dissociation and after 60 min complete dissocia- 
tion had taken place under the conditions used. On 
SDS-PAGE and HPLC analysis components cor- 
responding in I’& and retention time, respectively, 
to the original u-PA type used in the experiment 
reappeared (figs l-3). Unmodified PAI- was not 
recovered as judged by PAGE analysis, but instead 
a new component with an M, value approx. 4000 
lower appeared. On HPLC analysis, however, this 
component showed a similar retention behaviour 
to unmodified PAI- (figs 2,3, panels c,d, peak 
labelled N-term). The relative amount of the low- 
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Fig.3. Reaction between PAI- and low-M, u-PA monitored by reversed-phase HPLC. (a) Starting materials (separate, superimposed 
HPLC analysis), (b) complex formation, (c) partial and (d) complete dissociation. 
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Fig.4. Amino acid sequence around PAI- cleavage site (1) determined by direct sequence analysis of fragments obtained with u-PA 
(top) and CNBr (bottom) cleavage, respectively. 
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Fig.5. Alignment of PAI- cleavage site (1) sequence with the corresponding sequences of some other Arg-serpins, i.e. endothelial cell- 
type PA1 (PAI-1) [9], cY2-antiplasmin (cuz-AP) [14], antithrombin III (AT III) [15], Cl-inhibitor (Cl-inh) [16]. Identical residues in 
PAI- and other serpins in corresponding positions are boxed. 
M, HPLC component was not influenced by 
dissociation (figs 2,3, peak labelled C-term). 
PAI- and the new components recovered after 
the reaction were subjected to N-terminal amino 
acid sequence analysis. Neither PAI- itself nor the 
component with the similar retention time gave rise 
to any sequence. However, the low-M, HPLC 
component showed a sequence starting with Thr- 
Gly-His-Gly-Gly- (fig.4, top). From these results, 
it was concluded that the low-M, component cor- 
responds to the C-terminal part and the N- 
terminally blocked, high-M, component to the N- 
terminal part of PAI-2, the && values being about 
4000 and 40000, respectively. 
In an independent experiment PAI- was 
cleaved with CNBr after the Met residues, and then 
the fragments were separated by reversed-phase 
HPLC (not shown) and characterized by N- 
terminal sequencing. A 22-amino-acid residue 
fragment showed a sequence starting with Thr- 
Gly-Arg-Thr-Gly-His-Gly-, i.e. it contained the N- 
terminal part of the peptide released on reaction of 
PAI- with u-PA (fig.4, bottom). A 16-residue 
fragment starting with His-Lys-Ile-Thr-, was 
devoid of Met (or homoserine) in the composition, 
and therefore corresponds to the C-terminus of 
PAI- (not shown). From further sequence and 
amino acid analysis data, it was clear that the C- 
terminal peptide derived from the reaction with u- 
PA is composed of the final 19 residues of the 
former CNBr fragment and the complete fragment 
of the latter, i.e. the peptide contains 35 amino 
acid residues. This result is in good agreement with 
the decrease of 4000 in the M, value of PAI- dur- 
ing the reaction (fig.4). The sequence of the 
penultimate CNBr fragment also provided the 
reactive site sequence of PAI-2. A single Arg-Thr 
bond is cleaved during the reaction with the 
plasminogen activator, the cleavage of an arginyl 
bond being in agreement with the expected 
substrate specificity of u-PA. Identical results were 
obtained throughout with PA13 preparations 
from the two sources, human placenta and the 
human monocyte-like cell line U-937. 
The sequence around the cleavage site in PAI- 
is aligned with the corresponding sequence of other 
serine proteinase inhibitors in which an arginyl 
bond is cleaved (fig.5), i.e. other Arg-serpins 
[9,14-171. Within the short sequences compared 
only a few completely invariant amino acid 
residues are found in addition to the Arg at the 
cleavage site. It is noteworthy that the C-terminal 
peptide of PAI- is released on reaction with u-PA 
in the absence of a reducing agent even though this 
peptide contains Cys which might otherwise have 
been expected to disulfide-link the C-terminal and 
N-terminal parts of PAI- in an analogous way as 
these parts are linked in antithrombin III [15]. 
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